VistaGen Therapeutics, Inc. shares had a trading volume of 73K in the last trading session. Shares saw a steep decrease in trading volume of 80.32% under the normal average daily volume.
Investors are more bullish recently looking at the change in short interest. The firm recorded a fall in short interest from September 29, 2017 to October 13, 2017 of -20.44%. Short interest decreased from 167,275 to 133,089 over that timeframe. The days to cover decreased to 3.0 and the short interest percentage is 0.01% as of October 13.
The company is now unchanged from yesterday’s close of $0.00. Company shares are trading at $0.84 which is much lower than the 50 day moving average which is $1.39 and which is significantly below the 200 day moving average of $1.75. The 50 day moving average moved down $-0.55 and the 200 day average went down by -51.9348%.
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing product candidates for patients with central nervous system (CNS) diseases. The company’s lead product candidate, AV-101, which is in Phase IIa development as a augmentation option for adult patients suffering from treatment-resistant major depressive disorder (TRD). It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform, including drug rescue to develop proprietary small molecule new chemical entities (NCEs) for its internal drug candidate pipeline; and regenerative medicine (RM) using blood, cartilage, heart, and/or liver cells derived from hPSCs. In addition, the company offers CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. It has strategic collaborations with University Health Network, the McEwen Centre for Regenerative Medicine, and the Centre for the Commercialization of Regenerative Medicine for stem cell technology research, development, and cell production; and Norac Pharma, Pharmatek, and Synterys, Inc. to design, produce, and analyze AV-101 clinical trial materials and potential drug rescue NCEs. The company also has strategic relationships with Pharmaceutical Product Development, LLC; Cato Research, Ltd.; and Massachusetts General Hospital Clinical Trials Network and Institute for regulatory expertise and clinical development support. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California..